by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersPeak Performance Peptides

All Warning Letters

Peak Performance Peptides

Warning LetterOpen

3935 E Rough Rider Rd Unit 1016 Phoenix , AZ 85050 United States, (b)(6), (b)(7)(C)Issued Aug 24, 2026Center for Drug Evaluation and Research (CDER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateAug 24, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Peak Performance Peptides
Location: 3935 E Rough Rider Rd Unit 1016 Phoenix , AZ 85050 United States, (b)(6), (b)(7)(C)
FEI Number: N/A
Country: United States
Issue Date: August 24, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Subject

Unapproved New Drugs/Misbranded

Peak Performance Peptides FDA Warning Letter, August 24, 2026